Prosecution Insights
Last updated: April 19, 2026

Examiner: BAUSCH, SARAE L

Tech Center 1600 • Art Units: 1634 1699

This examiner grants 29% of resolved cases

Performance Statistics

28.7%
Allow Rate
-31.3% vs TC avg
652
Total Applications
+43.6%
Interview Lift
1464
Avg Prosecution Days
Based on 593 resolved cases, 2023–2026

Rejection Statute Breakdown

21.2%
§101 Eligibility
22.8%
§102 Novelty
20.4%
§103 Obviousness
28.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18266404 COMPOSITIONS AND METHODS FOR DETECTING AND TREATING ORAL CAVITY SQUAMOUS CELL CARCINOMA Non-Final OA THE UNIVERSITY OF CHICAGO
18114198 TEMPERATURE RESPONSIVE TAGS FOR FOOD ITEMS Non-Final OA MICROSOFT TECHNOLOGY LICENSING, LLC
17755519 Methods of Treatments Based Upon Molecular Response to Treatment Non-Final OA The Board of Trustees of the Leland Stanford Junior University
17928170 Compositions and Methods for Detecting Respiratory Viruses Including Coronaviruses Non-Final OA THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
18252185 METHOD FOR PREDICTING RESPONSIVENESS TO PLK1 INHIBITION Non-Final OA National University of Singapore
18156945 NOVEL DNA METHYLATION MARKERS ASSOCIATED WITH RENAL FUNCTION AND METHOD FOR PREDICTIING RENAL FUNCTION Non-Final OA The Chinese University of Hong Kong
17995246 NOVEL INSECTICIDAL TOXIN RECEPTORS AND METHODS OF USE Non-Final OA PIONEER HI-BRED INTERNATIONAL, INC.
17920931 METHODS FOR DETECTING TISSUE DAMAGE, GRAFT VERSUS HOST DISEASE, AND INFECTIONS USING CELL-FREE DNA PROFILING Non-Final OA CORNELL UNIVERSITY
18016188 COMPOSITIONS AND METHODS FOR DETECTING GENE FUSIONS OF RAD51AP1 AND DYRK4 AND FOR DIAGNOSING AND TREATING CANCER Non-Final OA UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
17765679 BIOMARKER, METHOD, KIT AND ARRAY FOR PREDICTING THERAPEUTIC EFFECTS OF BCG INTRAVESICAL INFUSION THERAPY IN TREATING BLADDER CANCER Final Rejection KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION
17909500 DNA DAMAGE REPAIR GENES IN CANCER Final Rejection The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
18039563 PCR KIT FOR DIAGNOSING ASTHMA OR ASTHMA EXACERBATION AND METHOD FOR PROVIDING INFORMATION FOR DIAGNOSING ASTHMA OR ASTHMA EXACERBATION BY USING SAME Final Rejection SOONCHUNHYANG UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION
18009936 METHODS FOR DETECTING AND PREDICTING BREAST CANCER Non-Final OA UCL BUSINESS LTD
17309348 DIFFERENTIAL METHYLATION Final Rejection UCL Business LTD
18490595 MULTI-MODAL METHODS AND SYSTEMS OF DISEASE DIAGNOSIS Final Rejection Universal Diagnostics, S.A
16765419 DIAGNOSTIC METHOD Final Rejection TOLREMO THERAPEUTICS AG
18324563 PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS Non-Final OA King Faisal Specialist Hospital & Research Centre
18137040 COLORECTAL CANCER SUBTYPE IDENTIFIER Non-Final OA Indivumed GmbH
17746748 METHODS AND COMPOSITIONS FOR DETECTING ecDNA Non-Final OA Ludwig Institute for Cancer Research Ltd
17057202 KINETICALLY PROGRAMMED SYSTEMS AND REACTIONS FOR MOLECULAR DETECTION Non-Final OA VALORISATION-RECHERCHE, LIMITED PARTNERSHIP
18164395 GENES AND GENE SIGNATURES FOR DIAGNOSIS AND TREATMENT OF MELANOMA Final Rejection MYRIAD MYPATH, LLC
17919118 cDNA, mRNA, PROTEIN, AND KIT AND SYSTEM FOR EVALUATING GLIOMA PROGNOSIS Final Rejection Beijing Neurosurgical Institute
17928400 CRISPR/CAS CHAIN REACTION SYSTEMS AND METHODS FOR AMPLIFYING THE DETECTION SENSITIVITY OF CRISPR-BASED TARGET DETECTION Non-Final OA UNIVERSITY OF FLORIDA RESEARCH FOUNDATION
17935281 REAGENT COMBINATION AND KIT FOR DETECTING LIVER CANCERS, AND USE THEREOF Final Rejection SANSURE BIOTECH INC.
17906211 PROGNOSTIC AND TREATMENT METHODS FOR THYROID CANCER Final Rejection Qualisure Diagnostics Inc.
17801724 SYSTEMS AND METHODS FOR THE DETECTION AND TREATMENT OF ASPERGILLUS INFECTION Final Rejection THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPT OF VETERANS AFFAIRS
17795312 METHODS FOR IMPROVED CANCER TREATMENT Non-Final OA CELLPHENOMICS GMBH
17712201 Clinical and Molecular Prognostic Markers for Liver Transplantation Final Rejection OPHIOMICS - INVESTIGAÇÃO E DESENVOLVIMENTO EM BIOTECNOLOGIA, SA
17598324 APPARATUS, SYSTEM AND METHOD Final Rejection Nanovery Limited

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month